Nanobiotix S.A. (NBTX)

NASDAQ: NBTX · IEX Real-Time Price · USD
6.54
+0.09 (1.40%)
Mar 4, 2024, 4:30 PM EST - Market closed
1.40%
Market Cap 310.77M
Revenue (ttm) 7.41M
Net Income (ttm) -64.60M
Shares Out 47.11M
EPS (ttm) -1.82
PE Ratio n/a
Forward PE 48.31
Dividend n/a
Ex-Dividend Date n/a
Volume 3,483
Open 6.46
Previous Close 6.45
Day's Range 6.35 - 6.49
52-Week Range 1.75 - 11.00
Beta 1.27
Analysts Buy
Price Target 11.00 (+68.2%)
Earnings Date Apr 22, 2024

About NBTX

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Grea... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 2020
Employees 102
Stock Exchange NASDAQ
Ticker Symbol NBTX
Full Company Profile

Financial Performance

In 2022, Nanobiotix's revenue was 4.78 million, an increase of 80.43% compared to the previous year's 2.65 million. Losses were -57.04 million, 21.4% more than in 2021.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to one analyst, the rating for NBTX stock is "Buy" and the 12-month stock price forecast is $11.0.

Price Target
$11.0
(68.20% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approa...

4 weeks ago - GlobeNewsWire

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based appro...

5 weeks ago - GlobeNewsWire

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR3 16.9 months median progression free survival (mPFS) and 23.1 mo...

4 months ago - GlobeNewsWire

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET

4 months ago - GlobeNewsWire

NANOBIOTIX Announces Closing of Global Offering

PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics...

4 months ago - GlobeNewsWire

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

PARIS and CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics...

4 months ago - GlobeNewsWire

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics...

4 months ago - GlobeNewsWire

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics...

4 months ago - GlobeNewsWire

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer (LAPC) established a favorable safety profile...

4 months ago - GlobeNewsWire

Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months

Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society...

5 months ago - GlobeNewsWire

NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology

Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST

5 months ago - GlobeNewsWire

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research

5 months ago - GlobeNewsWire

NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023

Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Upfront payment and first equity t...

5 months ago - GlobeNewsWire

Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023 Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023

5 months ago - GlobeNewsWire

NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

PARIS and CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approach...

6 months ago - GlobeNewsWire

NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference

PARIS and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approa...

6 months ago - GlobeNewsWire

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

PARIS and CAMBRIDGE, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approa...

7 months ago - GlobeNewsWire

NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023

PARIS and CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approa...

7 months ago - GlobeNewsWire

NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

PARIS and CAMBRIDGE, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO — NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approache...

8 months ago - GlobeNewsWire

Nanobiotix ADRs Jump Over 50% After Agreement With J&J's Janssen Pharmaceutical

American depositary receipts of Nanobiotix jumped over 50% in early trading on Monday after signing an agreement with J&J's Janssen Pharmaceutical to work on co-developing a drug to treat head and nec...

Other symbols: JNJ
8 months ago - Investopedia

Nanobiotix's stock soars after entering licensing, development deal with J&J's Janssen Pharmaceutica

Shares of Nanobiotix SA NBTX, +1.57% shot up 52.1% toward a 17-month high in premarket trading Monday, after the France-based biotechnology company announced a global licensing and co-development agre...

Other symbols: JNJ
8 months ago - Market Watch

NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approa...

8 months ago - GlobeNewsWire

NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

Reported €30.2 million in cash and cash equivalents as of March 31, 2023 Reported €30.2 million in cash and cash equivalents as of March 31, 2023

10 months ago - GlobeNewsWire

Nanobiotix stock more than triples, after biotech enters final negotiations with ‘major' drug maker on development of cancer treatment

The U.S.-listed shares of Nanobiotix S.A. NBTX blasted 221.7% higher on massive volume Friday, to pace all gainers trading on major U.S. exchanges, after the France-based biotechnology company said it...

10 months ago - Market Watch

NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company

PARIS and CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), today announced that the Company is entering into final contract negotiation...

10 months ago - GlobeNewsWire